Windtree Therapeutics Appoints Jamie McAndrew as CFO | Positive Phase 2b Results | Financial Agreements | Board Reshuffle
Windtree Therapeutics Inc. (NASDAQ:WINT) has named Jamie McAndrew as Senior Vice President and Chief Financial Officer, effective September 25, 2024. McAndrew, with a background in finance and accounting, has been with the company since 2013 and will continue her role as principal accounting officer. The company's board approved an increase in her annual base salary to $370,000.
In other news, Windtree Therapeutics reported positive results from its Phase 2b SEISMiC Extension Study of istaroxime, a drug for heart failure. The company also secured multiple funding agreements, resulting in a significant change in its share structure through a reverse stock split.
Additionally, the company underwent a board reshuffle with new independent directors appointed. These changes come as Windtree Therapeutics prepares for future clinical trials of istaroxime.
InvestingPro Insights:
- Market cap: $1.22 million
- Challenges: Cash burn rate, debt interest payments
- Stock performance: -70.53% in one month, -81.53% year-to-date
For investors seeking a more detailed analysis, InvestingPro offers 16 additional tips on Windtree Therapeutics. Stay informed about the financial health and market position of this biotechnology company.